Checkpoints in TNF-Induced Cell Death: Implications in Inflammation and Cancer

Trends in Molecular Medicine

Volumn 24, Issue 1, 2018, Pages 49-65

  Annibaldi, Alessandro ^a   Meier, Pascal ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

apoptosis; cell death; inflammation; necroptosis; RIPK1; TNF

Indexed keywords

CELL PROTEIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; PROTEIN MK2; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 1; SUCCINATE DEHYDROGENASE (UBIQUINONE); SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RIPK1 PROTEIN, HUMAN; UBIQUITIN;

CELL DEATH; CELL FATE; CELL KILLING; CHRONIC INFLAMMATION; ENZYME REGULATION; HUMAN; INFLAMMATION; MALIGNANT NEOPLASM; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

ANIMALS; CELL DEATH; HUMANS; INFLAMMATION; NEOPLASMS; NF-KAPPA B; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN;

EID: 85036666255     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2017.11.002     Document Type: Review

References (121)

1. Heaton, S.M., et al. Ubiquitin in the activation and attenuation of innate antiviral immunity. J. Exp. Med. 231 (2016), 1–13.
2. Senovilla, L., et al. Immunosurveillance as a regulator of tissue homeostasis. Trends Immunol. 34 (2013), 471–481.
3. Balkwill, F., Tumor necrosis factor and cancer. Nat. Rev. Cancer 9 (2009), 361–371.
4. Carswell, E.A., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 72 (1975), 3666–3670.
5. Wallach, D., The cybernetics of TNF: old views and newer ones. Semin. Cell Dev. Biol. 50 (2016), 105–114.
6. Apostolaki, M., et al. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr. Dir. Autoimmun. 11 (2010), 1–26.
7. Peyrin-Biroulet, L., et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 15 (2017), 25–36.
8. Winterfield, L.S., et al. Psoriasis treatment: current and emerging directed therapies. Ann. Rheum. Dis. 64:Suppl. 2 (2005), ii87–90 discussion ii91–92.
9. Wallach, D., et al. Concepts of tissue injury and cell death in inflammation: a historical perspective. Nat. Rev. Immunol. 14 (2014), 51–59.
10. Duprez, L., et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 35 (2011), 908–918.
11. Rickard, J.A., et al. TNFR1-dependent cell death drives inflammation in Sharpin-deficient mice. Elife, 3, 2014, e03464.
12. Gerlach, B., et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 471 (2011), 591–596.
13. Dondelinger, Y., et al. Poly-ubiquitination in TNFR1-mediated necroptosis. Cell. Mol. Life Sci. 73 (2016), 2165–2176.
14. Ting, A.T., Bertrand, M.J., More to life than NF-kappaB in TNFR1 signaling. Trends Immunol. 37 (2016), 535–545.
15. Peltzer, N., et al. Holding RIPK1 on the ubiquitin leash in TNFR1 signaling. Trends Cell Biol. 26 (2016), 445–461.
16. Luan, Q., et al. RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy. Autophagy 11 (2015), 975–994.
17. Weinlich, R., Green, D.R., The two faces of receptor interacting protein kinase-1. Mol. Cell 56 (2014), 469–480.
18. Polykratis, A., et al. Cutting edge: RIPK1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J. Immunol. 193 (2014), 1539–1543.
19. Dondelinger, Y., et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase inhibition. Cell. Death. Differ. 20 (2013), 1381–1392.
20. Wang, L., et al. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133 (2008), 693–703.
21. Berger, S.B., et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J. Immunol. 192 (2014), 5476–5480.
22. Rickard, J.A., et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157 (2014), 1175–1188.
23. Dillon, C.P., et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 157 (2014), 1189–1202.
24. Kaiser, W.J., et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 7753–7758.
25. Dannappel, M., et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513 (2014), 90–94.
26. Takahashi, N., et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513 (2014), 95–99.
27. Oberst, A., et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471 (2011), 363–367.
28. Micheau, O., Tschopp, J., Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003), 181–190.
29. Ea, C.K., et al. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22 (2006), 245–257.
30. Vanlangenakker, N., et al. TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members. Cell Death Dis., 2, 2011, e230.
31. Newton, K., et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ. 23 (2016), 1565–1576.
32. Harris, P.A., et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J. Med. Chem. 60 (2017), 1247–1261.
33. Lalaoui, N., et al. Targeting p38 or MK2 enhances the anti-leukemic activity of smac-mimetics. Cancer Cell 29 (2016), 145–158.
34. Brumatti, G., et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci. Transl. Med., 8, 2016, 339ra69.
35. Yatim, N., et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 350 (2015), 328–334.
36. Yatim, N., et al. Dying cells actively regulate adaptive immune responses. Nat. Rev. Immunol. 17 (2017), 262–275.
37. He, S., et al. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 20054–20059.
38. Kaiser, W.J., et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J. Biol. Chem. 288 (2013), 31268–31279.
39. Silke, J., et al. The diverse role of RIP kinases in necroptosis and inflammation. Nat. Immunol., 16, 2015, 889.
40. Lafont, E., et al. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J. 36 (2017), 1147–1166.
41. Wong, W.W., et al. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ. 17 (2010), 482–487.
42. Filliol, A., et al. RIPK1 protects hepatocytes from death in Fas-induced hepatitis. Sci. Rep., 7, 2017, 9205.
43. Rojas-Rivera, D., et al. When PERK inhibitors turn out to be new potent RIPK1 inhibitors: critical issues on the specificity and use of GSK2606414 and GSK2656157. Cell Death Differ. 24 (2017), 1100–1110.
44. Kelliher, M.A., et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8 (1998), 297–303.
45. Vanden Berghe, T., et al. Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis. J. Biol. Chem. 278 (2003), 5622–5629.
46. Haas, T.L., et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol. Cell 36 (2009), 831–844.
47. Rothe, M., et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83 (1995), 1243–1252.
48. Hsu, H., et al. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4 (1996), 387–396.
49. Gyrd-Hansen, M., Meier, P., IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 10 (2010), 561–574.
50. Ermolaeva, M.A., et al. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat. Immunol. 9 (2008), 1037–1046.
51. Draber, P., et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep. 13 (2015), 2258–2272.
52. Dynek, J.N., et al. c-IAP1 and UbcH5 promote K11-linked polyubiquitination of RIP1 in TNF signalling. EMBO J. 29 (2010), 4198–4209.
53. Newton, K., et al. Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134 (2008), 668–678.
54. Witt, A., Vucic, D., Diverse ubiquitin linkages regulate RIP kinases-mediated inflammatory and cell death signaling. Cell Death Differ. 24 (2017), 1160–1171.
55. Ori, D., et al. Essential roles of K63-linked polyubiquitin-binding proteins TAB2 and TAB3 in B cell activation via MAPKs. J. Immunol. 190 (2013), 4037–4045.
56. Rahighi, S., et al. Specific recognition of linear ubiquitin chains by NEMO is important for NF-kappaB activation. Cell 136 (2009), 1098–1109.
57. Kanayama, A., et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 15 (2004), 535–548.
58. Wang, C., et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412 (2001), 346–351.
59. Kearney, C.J., et al. Necroptosis suppresses inflammation via termination of TNF- or LPS-induced cytokine and chemokine production. Cell Death Differ. 22 (2015), 1313–1327.
60. Pasparakis, M., Vandenabeele, P., Necroptosis and its role in inflammation. Nature 517 (2015), 311–320.
61. Micheau, O., et al. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 21 (2001), 5299–5305.
62. Hughes, M.A., et al. Co-operative and hierarchical binding of c-FLIP and caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate. Mol. Cell 61 (2016), 834–849.
63. Weinlich, R., et al. Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Rep. 5 (2013), 340–348.
64. Dillon, C.P., et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep. 1 (2012), 401–407.
65. Legarda, D., et al. CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by Type I IFN. Cell Rep. 15 (2016), 2449–2461.
66. O'Donnell, M.A., et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13 (2011), 1437–1442.
67. Panayotova-Dimitrova, D., et al. cFLIP regulates skin homeostasis and protects against TNF-induced keratinocyte apoptosis. Cell Rep. 5 (2013), 397–408.
68. Bertrand, M.J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30 (2008), 689–700.
69. Moulin, M., et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J. 31 (2012), 1679–1691.
70. Varfolomeev, E., et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J. Biol. Chem. 283 (2008), 24295–24299.
71. Emmerich, C.H., et al. The linear ubiquitin chain assembly complex forms part of the TNF-R1 signalling complex and is required for effective TNF-induced gene induction and prevents TNF-induced apoptosis. Adv. Exp. Med. Biol. 691 (2011), 115–126.
72. Peltzer, N., et al. HOIP deficiency causes embryonic lethality by aberrant TNFR1-mediated endothelial cell death. Cell Rep. 9 (2014), 153–165.
73. Jaco, I., et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66 (2017), 698–710 e5.0.
74. Dondelinger, Y., et al. NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol. Cell 60 (2015), 63–76.
75. Dondelinger, Y., et al. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death. Nat. Cell Biol. 19 (2017), 1237–1247.
76. Jaco, I., et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66 (2017), 698–710.
77. Menon, M.B., et al. p38MAPK/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection. Nat. Cell Biol. 19 (2017), 1248–1259.
78. Walczak, H., TNF and ubiquitin at the crossroads of gene activation, cell death, inflammation, and cancer. Immunol. Rev. 244 (2011), 9–28.
79. Dondelinger, Y., et al. Regulation of RIPK1’s cell death function by phosphorylation. Cell Cycle 15 (2016), 5–6.
80. Kotlyarov, A., et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1 (1999), 94–97.
81. Neininger, A., et al. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem. 277 (2002), 3065–3068.
82. Kontoyiannis, D., et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999), 387–398.
83. Jadrich, J.L., et al. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development 133 (2006), 1529–1541.
84. Varfolomeev, E.E., et al. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9 (1998), 267–276.
85. Adhikari, A., et al. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26 (2007), 3214–3226.
86. Saccani, S., et al. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol. 3 (2002), 69–75.
87. Luedde, T., et al. IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9733–9738.
88. Gareus, R., et al. Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. Nat. Cell Biol. 9 (2007), 461–469.
89. Pasparakis, M., et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417 (2002), 861–866.
90. Li, Q., et al. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284 (1999), 321–325.
91. Tanaka, M., et al. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 10 (1999), 421–429.
92. Li, Z.W., et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J. Exp. Med. 189 (1999), 1839–1845.
93. Hu, Y., et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284 (1999), 316–320.
94. Li, Q., et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13 (1999), 1322–1328.
95. Takeda, K., et al. Limb and skin abnormalities in mice lacking IKKalpha. Science 284 (1999), 313–316.
96. Schmidt-Supprian, M., et al. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell 5 (2000), 981–992.
97. Vlantis, K., et al. NEMO Prevents RIP kinase 1-mediated epithelial cell death and chronic intestinal inflammation by NF-kappaB-dependent and -independent functions. immunity 44 (2016), 553–567.
98. Gaestel, M., et al. Targeting innate immunity protein kinase signalling in inflammation. Nat. Rev. Drug Discov. 8 (2009), 480–499.
99. Dumitru, C.D., et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103 (2000), 1071–1083.
100. Cargnello, M., Roux, P.P., Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75 (2011), 50–83.
101. Mohideen, F., et al. Quantitative phospho-proteomic analysis of TNFalpha/NFkappaB signaling reveals a role for RIPK1 phosphorylation in suppressing necrotic cell death. Mol. Cell. Proteomics 16 (2017), 1200–1216.
102. Geng, J., et al. Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis. Nat. Commun., 8, 2017, 359.
103. Degterev, A., et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4 (2008), 313–321.
104. Newton, K., et al. RIPK1 inhibits ZBP1-driven necroptosis during development. Nature 540 (2016), 129–133.
105. Vince, J.E., et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J. Cell Biol. 182 (2008), 171–184.
106. Boutaffala, L., et al. NIK promotes tissue destruction independently of the alternative NF-kappaB pathway through TNFR1/RIP1-induced apoptosis. Cell Death Differ. 22 (2015), 2020–2033.
107. Rahman, M.M., McFadden, G., Modulation of NF-kappaB signalling by microbial pathogens. Nat. Rev. Microbiol. 9 (2011), 291–306.
108. Peterson, L.W., et al. RIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense. J. Exp. Med. 214 (2017), 3171–3182.
109. Monack, D.M., et al. Yersinia signals macrophages to undergo apoptosis and YopJ is necessary for this cell death. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 10385–10390.
110. Philip, N.H., et al. Activity of uncleaved caspase-8 controls anti-bacterial immune defense and TLR-induced cytokine production independent of cell death. PLoS Pathog., 12, 2016, e1005910.
111. Mukherjee, S., et al. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312 (2006), 1211–1214.
112. Mittal, R., et al. Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 18574–18579.
113. Paquette, N., et al. Serine/threonine acetylation of TGFbeta-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 12710–12715.
114. Grivennikov, S.I., et al. Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
115. Medzhitov, R., Origin and physiological roles of inflammation. Nature 454 (2008), 428–435.
116. Swatek, K.N., Komander, D., Ubiquitin modifications. Cell Res. 26 (2016), 399–422.
117. Komander, D., Rape, M., The ubiquitin code. Annu. Rev. Biochem. 81 (2012), 203–229.
118. Dikic, I., et al. Ubiquitin-binding domains – from structures to functions. Nat. Rev. Mol. Cell Biol. 10 (2009), 659–671.
119. Fulda, S., Vucic, D., Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11 (2012), 109–124.
120. Vince, J.E., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131 (2007), 682–693.
121. Lu, J., et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 68 (2008), 9384–9393.